Neil Sankar

Dr. Sankar received his training in clinical research and tumor biology from NCI Bethesda, Maryland and since has held clinical development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclis, Fiveprime, Otsuka, Portola, CBT Pharmaceuticals, LSK biopharma and Rhizen Pharmaceuticals. As an expert in providing global clinical development and regulatory strategies for therapeutic drugs, Dr. Sankar has acted as the clinical lead in numerous phase I, II and III clinical trials. He is and was instrumental in filing the New Drug Applications for the antibody-drug conjugate Kadcyla and the B cell receptor signaling kinase inhibitor Ibrutinib. He has extensive experience in the application of U.S. Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Dr. Sankar is an active member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA , Drug information association (DIA) , European society of clinical oncology (ESMO), American Association for Cancer Research (AACR), Enterprising Pharmaceutical Professionals from the Indian Sub-Continent (EPPIC GLOBAL), Connective Tissue Oncology Society (CTOS), and TiE Silicon Valley. Neil Sankar received his M.D. degree from Bangalore University and internal medicine residency from University of West Indies, Kingston, Jamaica and trained in the UK and the Caribbean’s. He also holds a postgraduate degree in Public Health from Queensland University in Australia.